MIB FACTOR AGENTS OSTEOSARCOMA ALLIANCE
OSTEOSARCOMA CONFERENCE
COLUMBUS June 25th - 27th, 2026

2026 Scientific Glossary

Therapeutic Implications of Molecular Heterogeneity

Amplicon: A section of DNA containing cancer-promoting genes that has been copied many extra times, helping cancer cells grow and spread.

Cancer-associated fibroblasts (CAFs): Helper cells found around tumors. Instead of fighting the cancer, they support it by building a protective environment, helping the tumor grow, spread, and resist treatment.

CHK1 Pathway (Checkpoint Kinase 1): A primary defense mechanism in human cells that safeguards genome stability. It acts as a master coordinator of the DNA damage response (DDR) and cell cycle progression.

Chromatin conformation capture sequencing (HiC): This is a high-throughput molecular technique used to map the three-dimensional (3D) architecture of the entire genome. It identifies which genomic regions physically interact within the nucleus, revealing how DNA folds, loops, and organizes itself.

Chromosomal translocation: A genetic mutation where a segment of one chromosome breaks off and attaches to a non-homologous chromosome.

Chromothripsis: A rare event where a chromosome shatters into many pieces and gets stitched back together in the wrong order. This can result in complex genomic rearrangements, such as deletions, duplications, and inversions, all occurring at once, and can lead to cancer or other diseases.

CCNE1: A human gene that encodes a critical regulatory protein essential for controlling the cell cycle.

Extracellular matrix (ECM): The physical scaffolding around the tumor, made of proteins and fibers. Influences how cancer cells grow, move, and respond to treatment.

Extrachromosomal DNA (ecDNA): ecDNA in eukaryotes consists of circular, double-stranded DNA molecules found outside conventional chromosomes, primarily in the nuclei of cancer cells. These elements drive cancer evolution, treatment resistance, and high-level oncogene amplification, often leading to poor patient outcomes.

Fibroblast cells: The primary active cells of connective tissue, responsible for synthesizing the extracellular matrix (ECM) and collagen, which provide structural support to organs and tissues.

Gene amplification: This is the process of increasing the copy number of a specific segment of DNA, such as a single gene, without duplicating the entire genome. This directly leads to the overproduction of the corresponding RNA and proteins, acting as a powerful mechanism to amplify specific genetic traits or cellular functions.

Genomic instability: A high rate of mutations and genetic alterations within a cellular lineage. It happens when the body's DNA repair and replication systems fail, resulting in damaged, missing, or rearranged chromosomes. This instability is a primary driver of cancer and aging.

Global gene methylation: Acts as a master epigenetic switch, regulating gene expression, maintaining genome stability, and defining cell lineage without changing the DNA sequence itself.

2026 Scientific Glossary

Immune cells: Various immune cells, including lymphoid cells (e.g., T cells, B cells) and myeloid cells (e.g., macrophages, neutrophils, MDSCs) can be found in the TME. These cells can either promote or inhibit tumor growth and metastasis.

Laser capture microdissection (LCM): An automated laboratory technique used to isolate specific, microscopic cells from a mixed tissue sample under direct visual control. It allows researchers to harvest pure cell populations, or even single cells, from heterogeneous tissues, ensuring accurate molecular analysis without contamination from surrounding cells.

Multiomic profiling: Multiomic profiling is a holistic biological analysis approach that integrates data from multiple "omes", such as genomics, transcriptomics, proteomics, and metabolomics, to provide a comprehensive view of biological systems.

MYC: This is a family of regulator genes and proto-oncogenes that code for transcription factors, controlling vital cellular processes like growth, division, and death.

Optical genome mapping (OGM): This is a next-generation cytogenomic technology that images ultra-high molecular weight to detect structural variations (SVs) across the genome with high resolution and sensitivity. It identifies all types of SVs, including insertions, deletions, inversions, and translocations.

Outcome-linked biobank: A biorepository that connects biological samples (like blood and tissue) with detailed, long-term health and clinical data. By continuously tracking participants' electronic health records, they allow researchers to correlate biological and genetic profiles with real-world disease development.

OS cell lines: These are in vitro models used in cancer biology, drug screening, and preclinical therapy development. They retain the genetic, histological, and molecular characteristics of the primary bone tumors from which they are derived.

Oxford Nanopore Technologies (ONT): A DNA and RNA sequencing technology that reads genetic material directly by passing it through tiny pores and measuring changes in electrical signals to determine the sequence.

p53: Encodes a crucial tumor suppressor protein widely known as the "guardian of the genome". It plays a central role in regulating cell division and preventing cancer. When a cell's DNA becomes damaged, p53 halts cell division to allow for repairs or triggers cell death (apoptosis) if the damage is irreparable.

Passenger genes: These are genetic alterations that sit alongside critical disease-driving genes but provide no direct survival or proliferative benefit to the cell. While driver genes cause a disease to progress (like cancer), passenger genes are essentially just "along for the ride".

Prognostic biomarkers: A biological or clinical characteristic used to estimate the likely progression, recurrence, or survival rate of a disease in a patient. Unlike predictive biomarkers, which show how a patient will respond to a specific medication, prognostic markers indicate the innate aggressiveness of a condition regardless of treatment.

PTEN gene: This gene is a crucial tumor suppressor gene in humans. Its primary job is to regulate cell division and survival. By halting uncontrolled cell proliferation, signaling cells to stop dividing, and inducing apoptosis (programmed cell death), it prevents the growth of tumors.

2026 Scientific Glossary

Spatial transcriptomics: A technique that measures which genes are active in a tissue sample while preserving the exact location of those cells, allowing researchers to see where different biological processes are occurring within the tissue.

Tumor heterogeneity: The presence of different types of cells within a tumor, which can have distinct genetic profiles, making the cancer more complex and harder to treat.

Whole genome sequencing (WGS): This is a laboratory process that determines the exact order of all the DNA base pairs (A, T, C, and G) in an organism's entire set of genetic material. It provides a complete map of a person's DNA, including both the coding and non-coding regions.

Exploiting the Tumor Microenvironment

CXCL8: A potent inflammatory protein that is a primary chemical signal in the human body responsible for recruiting and activating immune cells, particularly neutrophils, to sites of infection, tissue injury, and inflammation.

Endothelial cells: Specialized, flat cells that form a continuous single-cell layer lining the interior surfaces of all blood vessels, lymphatic vessels, and the heart. Acting as a dynamic, metabolically active organ, it regulates vascular tone, blood flow, and clotting, while serving as a crucial semi-permeable barrier.

Fibrotic niche: A highly specialized, spatially confined microenvironment that forms at sites of chronic tissue injury and scarring. It is a complex ecosystem where various cells, signaling molecules, and structural proteins interact to sustain progressive fibrosis.

Fibroblast: The most abundant cells in animal connective tissue. They are responsible for making extracellular matrix (ECM) and collagen, which build the structural framework for tissues and organs. They play a critical role in healing wounds and maintaining tissue structure.

Fibronectin (FN1): This is a high-molecular-weight glycoprotein found in the extracellular matrix and blood plasma. It acts as a crucial "glue" that binds cells to the matrix and facilitates cellular adhesion, migration, growth, and differentiation.

Galectin-1: A protein that helps cells communicate and can suppress the immune system; in cancer, high levels of Galectin-1 may help tumors grow and evade immune attack.

IL1a (**Interleukin-1 alpha)**: A potent pro-inflammatory cytokine and "alarmin" encoded by the IL1A gene in humans. It is constitutively present in resting epithelial and immune cells. When cells are damaged or die, IL1A is released to trigger sterile inflammation, bridge innate immunity, and promote tissue repair.

IL6: A prominent protein and cytokine involved in regulating the body's immune system, inflammatory responses, and metabolism.

Integrin receptors: Integrins physically link the extracellular matrix (ECM) to the cell's cytoskeleton. They facilitate cell-cell and cell-matrix adhesion, driving bidirectional signaling that regulates cellular shape, mobility, proliferation, and survival.

2026 Scientific Glossary

JAG1: A protein that acts as a signaling molecule between cells, helping control cell growth and development; in some cancers, high JAG1 activity can promote tumor growth, spread, and resistance to treatment.

Kinase: A type of protein that acts like a molecular switch, helping control cell activities by turning other proteins on or off.

Lung epithelial cells: These act as a crucial, dynamic barrier against inhaled pathogens and environmental damage. They are essential for gas exchange, fluid balance, immune surveillance, and tissue repair.

Macrophage: Large, specialized white blood cells of the innate immune system that act as the body's primary cleanup crew and first line of defense. They engulf and digest cellular debris, pathogens, and cancer cells through a process called phagocytosis, while also initiating inflammation and repairing damaged tissues.

Mast cells: A type of white blood cell and a crucial part of your immune system. They act as the body's sentinel alert system, residing in tissues that interface with the outside world (like the skin, airways, and gut) to help fight off parasites, toxins, and pathogens.

Mesenchymal state: This refers to a cellular condition where cells lose their stationary, tightly-bound characteristics and adopt flexible, migratory, and invasive properties.

Metastatic niche: A supportive environment in another part of the body where cancer cells can settle, survive, and grow into new tumors.

Natural Killer (NK) cells: Specialized white blood cells that act as the immune system's rapid-response patrol, destroying virus-infected cells and cancerous threats on contact. As part of the innate immune system, they uniquely eliminate dangerous cells without requiring prior exposure or activation.

Osteoclasts: Specialized, multinucleated cells responsible for breaking down and resorbing bone tissue, acting as the body's "demolition crew" to remove old or damaged bone.

Profibrotic state: This is a pathological condition characterized by the abnormal, sustained activation of cells (like fibroblasts) and immune responses. It leads to the excessive production and accumulation of extracellular matrix proteins, driving tissue scarring, stiffening, and organ dysfunction.

Syndecan receptors: These receptors regulate fundamental cellular behaviors, including adhesion, migration, and cytoskeletal organization, by interacting with growth factors, extracellular matrix proteins, and primary receptors like integrins.

Stromal cells: Support cells that surround and help hold tissues together. In cancer, they’re part of the tumor’s neighborhood, helping build the structure around the tumor and sometimes sending signals that help the cancer grow, spread, or resist treatment.

T cells: A type of white blood cell that acts as the "special ops" division of your adaptive immune system. They identify and destroy infected or cancerous cells and direct the overall immune response to specific threats.

2026 Scientific Glossary

Transcriptomics: The study of all the RNA messages that cancer cells make from their DNA. By studying these messages (called transcripts), scientists can learn which genes are turned on or off in cancer, how the tumor is growing, and how it might respond to treatment.

Tumor microenvironment (TME): The cellular and non-cellular components surrounding tumor cells within the tumor tissue, including blood vessels, immune cells, and extracellular matrix, which play crucial roles in tumor growth, invasion, and metastasis.

Evolving Strategies for Local Control

Autologous bone graft: These are made from your own bone, taken from somewhere else in the body. The bone is typically harvested from the chin, jaw, lower leg bone, hip, or skull.

Cryogels: Sponge-like materials made by freezing and thawing gels, creating large interconnected pores that can hold cells, drugs, or biological molecules and are often used in tissue engineering and drug delivery.

FLASH RT: High-dose radiation that delivers radiation extremely quickly, which may better protect healthy tissue while still killing cancer cells.

High LET radiotherapy (linear energy transfer): A type of radiation treatment that uses highly energetic particles to cause severe damage to cancer cells, making it harder for them to survive and repair themselves.

Nanomaterials: Extremely small engineered particles, typically thousands of times thinner than a human hair, that can be designed to deliver cancer drugs directly to tumors, improve imaging, or enhance treatment effectiveness while reducing damage to healthy tissues.

Radiotherapy (RT): This is a localized cancer treatment that uses high-energy beams, such as X-rays or protons, to damage the DNA of cancer cells. This process destroys the cells' ability to multiply, ultimately shrinking tumors or destroying them completely while protecting surrounding healthy tissue.

SBRT (Stereotactic body radiation therapy): A highly precise form of radiation treatment that delivers very focused high-dose radiation to a tumor while minimizing damage to nearby healthy tissue.

Tumor treating fields: A non-invasive modality for cancer treatment that utilizes low-intensity electric fields to inhibit cancer cell proliferation and induce cell death.

Expanding Immunotherapy Approaches

Adoptive cellular therapy (ACT): A form of immunotherapy that collects, enhances, and reinfuses a patient's own immune cells (usually T cells) to target and destroy cancer. It acts as a highly personalized "living drug," yielding durable remissions for patients with aggressive hematologic and solid malignancies.

Antibody-drug conjugate: A targeted cancer treatment that combines an antibody that finds cancer cells with a powerful chemotherapy drug, allowing the drug to be delivered more directly to the tumor while limiting damage to healthy cells.

2026 Scientific Glossary

CAR T-cell therapy: Chimeric antigen receptor therapy involves genetically engineering a patient's T cells to express receptors that recognize specific proteins on cancer cells, enhancing their ability to target and destroy tumor cells.

Checkpoint Inhibitors: Immune checkpoints are regulatory molecules on immune cells or cancer cells that act as "brakes" to prevent overactivation of the immune system. Checkpoint inhibitors are drugs that block checkpoint proteins on immune cells or cancer cells, thereby unleashing the immune system to attack cancer cells.

Dual armored CAR T: Genetically engineered patient T-cells to target two distinct tumor antigens while simultaneously secreting two therapeutic proteins to overcome immunosuppressive tumors.

EPHA2: A protein found on the surface of many tumor cells.

Fibroblast activation protein (FAP): This is a cell-surface enzyme highly expressed on activated fibroblasts in tumor stroma, fibrosis, and chronic wounds. It is widely considered a key marker for cancer-associated fibroblasts (CAFs) and plays a major role in cancer progression, tissue remodeling, and immunosuppression.

Gamma-delta (γδ) T cells: A special type of immune cell that can quickly recognize and attack infected or cancerous cells as part of the body's natural defense system.

Immune evasion: Cancer cells find ways to hide from or block the immune system so they don't get attacked.

Immune response evaluation: Assessment of immune responses in patients undergoing immunotherapy, often using biomarkers such as cytokine levels, immune cell infiltration into tumors, or immune-related gene expression profiles.

Immunotherapy: Treatment that harnesses the body's immune system to recognize and attack cancer cells to enhance immune responses against tumor cells, leading to tumor regression or control.

NK Cell Therapy: A form of immunotherapy that involves the use of natural killer (NK) cells to target and destroy cancer cells. NK cells are a type of lymphocyte (a white blood cell) that plays a crucial role in the innate immune system's response to cancer and viral infections.

Surface proteins: Proteins found on the outside of cells. They act like ID tags or antennas, helping cells communicate, receive signals, or stick to other cells. In cancer, surface proteins can help tumors grow, spread, or hide from the immune system, and they're often used as targets for treatments like immunotherapy.

TGFβ: A pleiotropic cytokine, is a major mediator of immune suppression in the tumor microenvironment (TME), including in osteosarcoma.

Tumor-infiltrating lymphocytes (TILs): Immune cells that have migrated into a tumor, often indicating an active immune response against the tumor. Strategies to isolate and expand TILs for adoptive cell therapy are being explored in pediatric sarcomas.

2026 Scientific Glossary

Molecular Pathways and Therapeutic Vulnerabilities

Bromodomain: A part of a protein that helps control how genes are switched on or off in cells.

BRD4: A protein that helps turn genes on and off; in many cancers, it can drive tumor growth by activating genes that cancer cells need to survive and multiply, making it a target for new cancer therapies.

Bru-sequencing: Bromouridine sequencing is an advanced molecular biology technique that maps and measures actively transcribed (nascent) RNA in living cells. By briefly exposing cells to bromouridine, newly synthesized RNA is tagged, isolated, and sequenced, allowing researchers to monitor real-time gene expression and RNA degradation independent of older, pre-existing RNA.

Cell fates: Whether a cancer cell survives, dies, divides, or changes into another type of cell during tumor growth or treatment.

Cohesin collapse: When the proteins that help keep DNA organized and properly separated stop working correctly, causing mistakes in cells.

CUT&Tag (Cleavage Under Targets & Tagmentation): A laboratory technique that identifies where proteins bind to DNA, helping researchers understand which genes are being regulated in cancer cells and other tissues.

DNA damage repair: The process cells use to find and fix damage in their genetic material to help keep the cell healthy and functioning properly.

ERK signaling: A communication pathway inside cells that tells them when to grow, divide, or survive; in many cancers, this pathway becomes overactive, driving uncontrolled tumor growth.

LRRC15: A protein often found on the surface of osteosarcoma cells and the tumor-supporting tissue around them.

Radiotheranostics: A medical approach that uses radioactive substances both to find cancer in the body and to treat it at the same time.

Samuraciclib: An orally available cyclin-dependent kinase 7 (CDK7) inhibitor that targets cancer cell growth.

Serial imaging: This consists of the sequential acquisitions over time of images of the same patient to monitor changes of a pathological area and the effects of therapies/treatments.

Spatial heterogeneity: Different areas of the same tumor can contain different types of cancer cells, immune cells, and biological activity, which can affect how the tumor grows and responds to treatment.

Temporal heterogeneity: A tumor can change over time—developing new characteristics, mutations, or treatment resistance as it grows or responds to therapy.

2026 Scientific Glossary

TGFβ: A pleiotropic cytokine, is a major mediator of immune suppression in the tumor microenvironment (TME) including in osteosarcoma.

Topotecan: A chemotherapy medication and topoisomerase inhibitor, it works by blocking the enzyme that cells need for DNA repair and division, which ultimately kills the cancer cells.

Tumor lysis: Occurs when a large number of cancer cells die rapidly and release their contents into the bloodstream, which can overwhelm the body and cause serious complications affecting the kidneys, heart, and other organs.

Addressing Chemoresistance in Osteosarcoma

EGFR (Epidermal Growth Factor Receptor): This gene encodes a transmembrane protein responsible for regulating cell growth, division, and survival. Mutations or overactivity in this gene are heavily associated with various cancers.

Extinction therapy: An emerging, evolution-based cancer treatment strategy. It operates on the theory that instead of using constant maximum-dose drugs, doctors should treat the tumor in precise, sequential waves to drive the vulnerable, diminished cancer cell population to extinction before drug resistance can develop.

Extracellular matrix (ECM): The physical scaffolding around the tumor, made of proteins and fibers. Influences how cancer cells grow, move, and respond to treatment.

KRAS: This is a critical oncogene that controls cell growth and division. When mutated, it can cause cells to multiply uncontrollably, making it a primary driver for many aggressive cancers.

Multidrug resistance (MDR): Resistance to multiple anti-cancer drugs that belong to different classes or have different mechanisms of action, making treatment challenging and limiting therapeutic options.

Organoids: Miniaturized, three-dimensional tissues grown in the lab from stem cells. They mimic the structure, complexity, and functions of actual human organs. Ranging from a fraction of a millimeter to several millimeters, they are revolutionizing disease modeling, drug screening, and personalized medicine.

Patient-derived xenograft (PDX) models: These are in vivo cancer research platforms created by implanting fresh human tumor tissue directly into immunodeficient or humanized mice. Because they retain the original tumor's cellular heterogeneity, genetic mutations, and microenvironment, they are widely used for preclinical drug screening and personalized medicine.

Phosphorylation: A fundamental cellular process that involves the addition of a phosphate group to a molecule, such as a protein or sugar. This highly reversible mechanism acts as a molecular "on/off" switch, driving essential functions like metabolism, cell signaling, growth, and apoptosis.

Primary resistance: Resistance that occurs initially, either due to inherent genetic factors or acquired mutations present before treatment initiation.

2026 Scientific Glossary

Proteomics: The large-scale, comprehensive study of the proteome, the entire set of proteins produced or modified by an organism, tissue, or cell at any given time.

Ras signaling pathway: The Ras signaling pathway is a master cellular cascade that relays extracellular signals (like growth factors) from the cell membrane to the nucleus, regulating critical processes such as cell proliferation, survival, and differentiation.

Resistance: The ability of cancer cells to survive and continue growing despite treatment, often due to genetic mutations or changes in cell behavior that make the cancer more resilient.

RNA sequencing (RNA-Seq): A next-generation sequencing method used to analyze the entire set of RNA molecules (the transcriptome) in a cell or tissue. It allows researchers to determine which genes are actively expressed, measure their exact abundance, and identify alternative splicing patterns or novel transcripts.

Translational research: The process of rapidly turning basic scientific discoveries into practical solutions, such as new drugs, devices, or treatments, that directly benefit human health.

Novel Therapeutic Modalities and Delivery Strategies

Alpha particle-emitting isotopes: Radioactive atoms that decay by emitting an alpha particle (a helium-4 nucleus). Because of their high linear energy transfer and short tissue range (under 0.1 mm), they are highly effective at destroying targeted cancer cells while sparing surrounding healthy tissue.

Antibody-radionuclide complex: A precision medicine tool that links a tumor-targeting monoclonal antibody to a radioactive payload. It is used to deliver localized radiation directly to cancer cells while sparing healthy tissue.

Antibody drug conjugate: ADCs are a targeted cancer treatment that uses an antibody to deliver a powerful drug directly to cancer cells while limiting damage to healthy cells.

CADM1: (Cell Adhesion Molecule 1) is a transmembrane glycoprotein that functions as a tumor suppressor, adhesion molecule, and potential therapeutic target. It is crucial for cell-cell interaction in neural, epithelial, and immune tissues, where low expression often correlates with poor prognosis in various cancers.

Cell surface expression: Proteins or markers that are displayed on the outside of a cell, where they can help cells communicate and interact with their environment.

Chromatin: A complex of DNA, RNA, and proteins that forms chromosomes within the nucleus of eukaryotic cells. Its primary function is to package massive lengths of DNA into a highly compact, organized form that fits inside the microscopic nucleus, while also serving as a dynamic regulator of gene expression.

Folate receptor alpha: A cell-surface protein that binds and transports folate (vitamin B9) into cells, supporting DNA synthesis and cell growth. While expressed in only trace amounts in healthy adult tissues, it is highly overexpressed in several cancers, making it a major biomarker and target for precision oncology.

2026 Scientific Glossary

GD2: A well-known tumor-associated antigen. While rarely present in healthy adult tissue, it is highly overexpressed on several cancers, making it a key target for immunotherapy.

HER2: Human epidermal growth factor 2 is a protein that promotes cell growth in certain cancers.

Intertumoral heterogeneity: The differences between tumors in different patients or even between tumors in the same patient if they have more than one. It means that each tumor can have its own unique set of characteristics, like genetic changes or how it grows. This variation makes each cancer case different, which is why treatments that work for one person might not work for another.

Intratumoral heterogeneity: Within a single tumor, there are different types of cancer cells, each with its own characteristics. Some of these cells may grow faster, be more resistant to treatment, or behave differently, making the tumor more complex and harder to treat effectively.

Messenger RNAs (mRNA): A single-stranded molecule that carries genetic instructions from DNA to a cell's protein-making machinery. It acts as a temporary molecular blueprint, directing cells to synthesize specific proteins required for cellular function, growth, and immune responses.

miR-34a: A critical tumor-suppressive microRNA that regulates gene expression, often downregulated in various cancers. It is a direct target of the p53 tumor suppressor protein, inhibiting tumor proliferation, metastasis, and chemoresistance by targeting oncogenes like SIRT1, MYC, and CD44.

MicroRNA: A small molecule in cells that helps control how genes are turned on or off by regulating protein production.

MicroRNA therapy: A developing therapeutic approach that uses small, non-coding RNA molecules to regulate gene expression, targeting diseases like cancer, cardiovascular, and kidney diseases by either mimicking tumor-suppressive miRNAs or inhibiting oncogenic miRNAs (oncomiRs).

p53: Encodes a crucial tumor suppressor protein widely known as the "guardian of the genome". It plays a central role in regulating cell division and preventing cancer. When a cell's DNA becomes damaged, p53 halts cell division to allow for repairs or triggers cell death (apoptosis) if the damage is irreparable.

Peptide: Short chains of amino acids (the building blocks of proteins) that act as crucial messengers in the body. Naturally occurring in all cells, they regulate vital functions such as hormone production, inflammation, and tissue repair.

Radiotherapy: High-energy beams, such as X-rays or protons, are used to damage the DNA of cancer cells and shrink tumors. It is a highly localized treatment designed to destroy cancer cells while sparing surrounding healthy tissue. It is often used before or after surgery or chemotherapy.

Small-interfering RNAs (siRNAs): Known as RNA interference (RNAi), this mechanism allows for precise gene silencing and holds major promise for treating cancers, viral infections, and genetic disorders.

Therapeutic payload: The active, disease-killing agent (drug, gene, or cell) delivered to a specific target in the body, most notably in Antibody-Drug Conjugates (ADCs) for cancer. These agents are designed to maximize the destruction of diseased cells while sparing healthy tissue, often acting via targeted delivery mechanisms.

2026 Scientific Glossary

Clinical Trials

177Lutetium (177Lu) radionuclide payload: This acts as a microscopic "warhead" attached to a homing molecule that navigates through the body, delivering short-range cell-killing radiation directly to the tumor.

Apoptosis: The process of programmed cell death used by multicellular organisms to eliminate damaged, infected, or unnecessary cells.

Apheresis: This is a medical technology where blood is withdrawn from a person, passed through a machine that separates and removes specific blood components (such as plasma, platelets, or white blood cells), and the remaining blood is returned to the body.

Adverse event: Any undesirable or unexpected medical occurrence or side effect experienced by a participant during or after receiving treatment in a clinical trial, regardless of its causality.

Basement membrane extract (BME): This is a complex mixture of extracellular matrix proteins (such as laminin, collagen IV, entactin, and heparan sulfate proteoglycans) secreted by mouse tumor cells.

Blinding: A method used in clinical trials to prevent bias by keeping certain information (e.g., treatment assignment, outcome assessments) concealed from participants, researchers, or both. Blinding can be single-blind (participants unaware), double-blind (both participants and researchers unaware), or triple-blind (participants, researchers, and outcome assessors unaware).

Clinical trial: A research study designed to evaluate the safety, efficacy, and/or side effects of new treatments, interventions, or diagnostic procedures in human patients.

Control group: The group of participants in a clinical trial that receives the standard treatment or placebo, used as a comparison against the experimental treatment group to evaluate its safety and efficacy.

Cyclophosphamide: A powerful prescription medication and chemotherapy drug. It works by damaging cellular DNA, slowing the growth of cancer cells, and suppressing the immune system.

Data monitoring committee (DMC): An independent group of experts responsible for reviewing and monitoring the safety and efficacy data from a clinical trial to ensure participant safety and data integrity.

DFMO (DL-alpha-difluoromethylornithine) or eflornithine: A drug that blocks cells from making certain molecules they need to grow and divide by inhibiting an enzyme called ornithine decarboxylase (ODC), which is involved in producing polyamines, small molecules that help cells grow.

Domatinostat: This is an investigational, orally bioavailable small-molecule drug being studied in oncology. It works as a selective inhibitor of Class I histone deacetylases (HDACs), which helps remodel chromatin, reactivate tumor-suppressor genes, and trigger cancer cell apoptosis.

Dose Limiting Toxicity (DLT): A term used in clinical trials to describe the most severe adverse event or side effect that occurs at a particular dose level of an investigational drug or treatment. DLTs play a

crucial role in determining the maximum tolerated dose (MTD) of a treatment, which is the highest dose that can be administered safely without causing unacceptable toxicity.

Endpoint: A specific measure or outcome used to evaluate the efficacy, safety, or clinical benefit of a treatment in a clinical trial, such as progression-free survival, overall survival, response rate, or quality of life.

Experimental treatment: The investigational treatment or intervention being studied in a clinical trial, which may include new drugs, therapies, procedures, or combinations of treatments.

Folate receptor-alpha (FOLR1): This is a protein that regulates the transport of the B-vitamin folate into cells. Encoded by the FOLR1 gene, it is crucial for DNA synthesis, repair, and brain development. This protein has been found to be expressed by a majority of osteosarcoma, making it an attractive target for adoptive cellular therapies such as chimeric antigen receptor (CAR) T cells.

Fludarabine: A chemotherapy drug and targeted conditioning agent to treat blood cell cancers, particularly chronic lymphocytic leukemia (CLL).

Follow-up period: The period of time during and after the completion of a clinical trial when participants are monitored and evaluated for treatment outcomes, adverse events, and long-term effects of treatment.

Informed consent: The process by which patients or their legal guardians are provided with detailed information about the clinical trial, including its purpose, procedures, potential risks and benefits, and alternatives, and voluntarily agree to participate in the study.

LRRC15: A protein often found on the surface of osteosarcoma cells and the tumor-supporting tissue around them.

Lymphodepleting chemotherapy: This is a short course of chemotherapy administered immediately before Adoptive Cell Therapies (like CAR-T or TIL therapy) to destroy existing immune cells. This "preconditioning" reduces the body's immune suppression, allowing for better expansion, persistence, and anti-tumor activity of the newly infused cells.

Maximum tolerated dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.

Non-therapeutic trials: Trials that do not provide a treatment to patients, but instead study important factors that help advance the understanding of cancer and its impact. For example, some non-therapeutic studies collect tissue specimens to examine the cellular structure of a cancer tumor. Other studies track epidemiological information such as the long-term health effects of chemotherapy. Non-therapeutic studies often lead to therapeutic ones.

Objective response rate (ORR): The percentage of people in a study or treatment group who have a partial response or complete response to the treatment within a certain period of time.

Pharmacokinetics: This is the branch of pharmacology that determines how the body interacts with a drug over time. It is summarized by the acronym ADME, which tracks the journey of a substance from the moment it enters your system to the point it leaves.

2026 Scientific Glossary

Phase I studies: A Phase 1 clinical trial is the first study of a new treatment in people, designed primarily to determine its safety, side effects, and appropriate dose.

Phase II studies: A Phase 2 study tests whether a treatment shows signs of working in patients while continuing to monitor its safety and side effects.

Phase III studies: A Phase 3 clinical trial compares a new treatment to the current standard treatment (or placebo) in a larger group of patients to confirm how well it works and monitor its safety.

Placebo: An inactive substance or treatment that resembles the experimental treatment but has no therapeutic effect, used in clinical trials to assess the efficacy of the experimental treatment compared to no treatment or standard treatment alone.

Polyamines: These are responsible for cell proliferation and the inhibition of apoptosis through a variety of cellular signaling pathways.

Progression-free survival (PFS): The length of time during and after treatment that a patient's cancer does not grow, spread, or get worse.

Protocol: A detailed plan outlining the objectives, design, methodology, eligibility criteria, treatment regimens, and endpoints of a clinical trial. The protocol is developed by researchers and approved by regulatory authorities and institutional review boards (IRBs) before the trial begins.

Pulmonary metastasis assays (PuMA): This is an ex vivo laboratory technique used to study the progression of cancer cells as they spread and colonize the lung microenvironment.

Radionuclide payload: A highly potent radioactive atom used in targeted oncology, such as in Radionuclide Drug Conjugates (RDCs) or Radiopharmaceutical Therapy (RPT). It acts as a guided warhead that is chemically bound to a targeting ligand (like an antibody) to irradiate and destroy cancer cells while sparing healthy tissue.

Randomization: The process of assigning participants to different treatment groups (e.g., experimental treatment vs. standard treatment or placebo) in a clinical trial using a random method, such as computer-generated randomization or randomization tables.

RP2D: The primary focus of any Phase I oncology trial is to find the Recommended Phase II Dose (RP2D), by ascertaining the maximum tolerated dose (MTD), the maximal dose with the dose-limiting toxicities (DLT) not exceeding a pre-set limit.

Sirolimus: This is a potent immunosuppressive medication. It works by calming the immune system and blocking proteins involved in cell division.

Therapeutic trials: Trials that enroll patients and provide a specific treatment to the patients to study its impact on cancer.

Tumor homing: This is the ability of engineered CAR T cells to actively migrate through the bloodstream and infiltrate solid tumors. For solid cancers, overcoming this physical and biological barrier is a major hurdle; unlike blood cancers, solid tumors lack specific molecular signals to draw T cells in.